SEC Form 4 · accession 0001493152-17-002849
PetLife Pharmaceuticals, Inc. · PTLF
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Vyvyan Campbell
Director · 10% Owner
Period of report
May 30, 2015
Accepted (ET)
Mar 24, 2017 · 7:47 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001354591
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | May 30, 2015 | P | 50,210 | $0.75 | A | 50,210 | D | |
| Common StockF1 | Nov 9, 2015 | P | 100,000 | $0.25 | A | 150,210 | D | |
| Common StockF1 | May 15, 2016 | P | 218,470 | $1.25 | A | 368,680 | D | |
| Common StockF2 | Oct 27, 2016 | A | 1,200,000 | $0.50 | A | 1,568,680 | D | |
| Common Stock | Feb 23, 2017 | P | 40,000 | $0.25 | A | 1,608,680 | D | |
| Common StockF2,F3 | Feb 23, 2017 | A | 9,484,555 | $0.50 | A | 9,484,555 | I | By O'Dwyer Friends and Value Irrevocable Trust |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Adjusted for the issuer's 1-for-5 reverse stock split effected in September 2016.
- F2For services valued at $0.50/share.
- F3Ms. Campbell is the trustee of the trust and has sole voting and dispositive power with respect to shares held in the name of the trust.